NIKKEI 225
37,024.18 -1,055.52 (-2.77%) HANG SENG
16,200.58 -185.29 (-1.13%) CRUDE OIL
84.47 +1.74 (+2.10%) GOLD FUTURES
2,397.50 -0.50 (-0.02%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
50,055.20 +426.62 (+0.86%)
MorphoSys AG (MOR.SG)
- Zacks
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
- Zacks
Novartis (NVS) to Undertake Job Cuts in Development Department
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.
- Business Wire
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
PLANEGG/MUNICH, Germany, April 11, 2024--The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as "Novartis"), recommending that shareholders accept the offer and tender their MorphoSys shares. Novartis offers MorphoSys shareholders € 68.00 per share in cash, representing a total e
